LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

This study is testing a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma (a blood cancer) that has come back or stopped responding to at least three prior lines of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. LCAR-F33S uses engineered immune cells to attack and kill myeloma cells. **You may be eligible if...** - You are 18 or older - You have multiple myeloma with measurable disease - You have received at least 3 prior lines of treatment (including all three major drug classes) - Your disease is still active with measurable markers - You are well enough to participate (ECOG 0–2) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have previously received a therapy targeting the FcRH5 protein - You have plasma cell leukemia, Waldenstrom's disease, POEMS syndrome, or AL amyloidosis - You are positive for HIV, hepatitis B, or hepatitis C - You have a life-threatening allergy to CAR-T cell ingredients (including DMSO) - You are pregnant, breastfeeding, or planning pregnancy within 1 year of treatment - You are enrolled in another clinical study Talk to your doctor to see if this trial is right for you.